Pre-clinical trials aim to provide preliminary information into the efficacy, pharmacokinetics and safety of our cannabinoid-based medicines

Enhanced Distillate Capture and Dissolution Matrix (EDCDM) technology

Zelira has successfully developed and demonstrated enhanced dissolution of cannabinoids using its enhanced distillate capture and dissolution matrix (EDCDM)

Before this breakthrough technology was developed by Zelira cannabis manufacturers had difficulty in formulating and developing free flow solid oral dosage forms based on cannabinoid distillate. This is due to the non-uniformity of cannabinoid distillate and its separation from the powder bed. EDCDM technology, developed by Zelira, resolves this problem by creating the capacity to capture distillate in a unique and proprietary matrix. When combined with the cannabinoid distillate, it creates a free-flowing powder base for capsules and tablets.

Enhanced Distillate Capture and Dissolution Matrix (EDCDM)



This novel matrix absorbs the distillate into a nano porous silicate particle where the distillate is effectively trapped in the structure of the silicate rendering the powder bed dry. As a result, this prevents the distillate from separating from the powder bed during encapsulation and under the compression forces utilised in tableting thus opening new ways to develop pharmaceutical grade, cannabinoid-based medicines in solid oral dosage forms such as capsules and tablets.


CBD Encapsulation and Improved Oral Bioavailability

Sponsored by Zelira Therapeutics, researchers from Curtin University developed oral capsules containing cannabidiol (CBD) that enabled more CBD to penetrate the brain. The new capsulated form protects the CBD from oxidation and degradation by light which helps to extend product shelf-life. The findings support the development of CBD-based treatments for a range of neurological disorders including diabetes associated dementia, Alzheimer’s disease, multiple sclerosis and traumatic brain injuries.


  • Majimbi M, Brook E, Galettis P, Eden E, Al-Salami H, Mooranian A, et al. (2021) Sodium alginate microencapsulation improves the short- term oral bioavailability of cannabidiol when administered with deoxycholic acid. PLoS ONE 16(1): e0243858

Brain cancer

Around 15 – 20% of brain cancers in children is caused by medulloblastoma.1 It’s the most common form of brain tumour in children and also the most malignant.

Mortality from medulloblastoma remains significant and many survivors suffer from severe treatment-related effects of radiation and cytotoxic chemotherapy.

Zelira’s research collaboration has the potential to provide an alternative treatment option.

Pancreatic cancer

Pancreatic cancer is the 8th most common cancer in both men and women in Australia and the 12th most common cancer globally. 1

Breast cancer

Breast cancer is the most common cancer in women world-wide, with 2.3 billion women diagnosed in 2020.1 There are many different types of breast cancer with HER2 positive breast cancer making up around 20 – 30% of all breast cancers.2


  2. Engel R, Kaklamani V, HER2-positive breast cancer. Drugs 2007:67, 1329-1241

Neurological Conditions

Start typing and press Enter to search

Shopping Cart